OliX Pharmaceuticals Begins Phase 1 Clinical Study of RNAi Therapeutic for Androgenic Alopecia

OliX Pharmaceuticals has announced the start of a Phase 1 clinical trial for its RNAi therapeutic, OLX72021, which is being developed to treat male-pattern baldness. The study will assess the drug's safety, tolerability and pharmacokinetics in single intradermal injections in up to 30 healthy males with androgenic alopecia over an eight-week period. Participants will be split into five cohorts a..